Rhinomed News

Rhinomed Records Positive Year On Year Result

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, can report its FY 20 Q4 results and preliminary unaudited full year results. After a record FY20 Q3 result the company was on track to reach its full year planned targets. Confirmation during the quarter that … Read more

Rhinomed Delivers Major Milestone: Pronto to Appear in 6,336 New Stores in US

Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, today announces it has received purchase orders confirming a major distribution expansion of its Pronto Clear nasal decongestion technology within one of the largest and leading pharmacy and drugstore chains in the USA. Read a full … Read more

RNO Signs 12 Year Licensing Agreement With USA’s Largest Medical Cannabis Operator

Rhinomed (ASX:RNO) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.). Read a full copy of the report here.

Appendix 4E Preliminary Final Report

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report Read a full copy of the report here.

Business Update – June Quarter Cash Flow Report

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k – a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17. This came off the back of another … Read more

RNO & US Based Columbia Care To Develop Nasally Delivered Dose Controlled Cannabis Based Medicines

RHINOMED & US BASED COLUMBIA CARE TO DEVELOP NASALLY DELIVERED DOSE CONTROLLED CANNABIS BASED MEDICINES June 21, 2018, ​ Melbourne, Australia. Melbourne based nasal respiratory company Rhinomed (ASX:RNO) is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC (“Columbia Care”) to license Rhinomed’s nasal platform for the delivery of medical … Read more

Mute Expands Ranging in Leading US Pharmacy

MUTE EXPANDS RANGING IN LEADING US PHARMACY – OVER 1100 NEW STORES ADDED June 19, 2018, ​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has expended its relationship with one of America’s largest pharmacy retailer – CVS. The Company has now received initial purchase orders confirming that Mute … Read more

New Retailer to Stock Mute in 3000 New USA Pharmacies

NEW RETAILER TO STOCK MUTE IN 3000 NEW USA PHARMACIES May 28 2018, ​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for stock from a new retailer. The retailer is one of America’s largest … Read more

Half Yearly Report and Accounts

HALF YEARLY REPORT AND ACCOUNTS   February 28, 2018.​ Melbourne, Australia. Rhinomed (ASX:RNO or “the Company) releases its half yearly report and accounts. Read a full copy of the report here.

Rhinomed​ to Present at International Investor Conferences

RHINOMED​ ​TO PRESENT AT INTERNATIONAL INVESTOR CONFERENCES March 5, 2018.​ Melbourne, Australia. Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise it will exhibit and present at two major investor conferences in the USA and the UK in March. Read a full copy of the announcement here.

Rhinomed​ ​Change in Executive Remuneration

March 2, 2018.​ Melbourne, Australia.Rhinomed (ASX:RNO or “the Company) engaged Crichton and Associates, remuneration consultants to review its remuneration policies and make recommendations on the Company’s remuneration levels based on the market conditions and expectations. Read a full copy of the announcement here.

Rhinomed​ ​Completes AUD $3.6M Capital Raise

Rhinomed Limited (ASX: RNO or “the Company”) a leading sleep and nasal respiratory technology company has successfully undertaken an AUD$3.6 million placement to institutional and sophisticated private investors at $0.15 per share. Read a full copy of the announcement here.